A Study of Adavosertib as Treatment for Uterine Serous Carcinoma (ADAGIO)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04590248|
Recruitment Status : Completed
First Posted : October 19, 2020
Last Update Posted : February 23, 2023
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Uterine Serous Carcinoma||Drug: Adavosertib||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||109 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase 2b, Open-label, Single-arm, Multi-centre Study Assessing the Efficacy and Safety of Adavosertib as Treatment for Recurrent or Persistent Uterine Serous Carcinoma|
|Actual Study Start Date :||November 30, 2020|
|Actual Primary Completion Date :||May 23, 2022|
|Actual Study Completion Date :||February 7, 2023|
Subjects will receive adavosertib 300 mg administered orally, once daily on Days 1 to 5 and Days 8 to 12 of a 21-day treatment cycle.
The subjects will receive oral adavosertib 300 mg, once daily on Days 1 to 5 and Days 8 to 12 of a 21-day treatment cycle.
Other Name: AZD1775
- Objective response rate (ORR) [ Time Frame: From baseline to approximately 24 months ]The percentage of subjects with measurable disease at baseline who have a confirmed complete response (CR) or partial response (PR), as determined by Blinded Independent Central Review (BICR) per RECIST v1.1
- Duration of response (DoR) [ Time Frame: From baseline to approximately 24 months ]The time from the date of first documented response until date of documented progression per RECIST v1.1 as assessed by BICR, or death in the absence of disease progression
- Depth of response [ Time Frame: From baseline to approximately 24 months ]Absolute change and percentage change from baseline will be based on RECIST v1.1 target lesions measurements
- Progression free survival (PFS) [ Time Frame: From baseline to approximately 24 months ]The time from first dose until the date of objective disease progression or death (by any cause in the absence of progression), derived using RECIST v1.1 assessments based on BICR data
- PFS6 [ Time Frame: From baseline up to 6 months ]The proportion of subjects alive and progression free at 6 months by Kaplan-Meier estimate
- Overall survival (OS) [ Time Frame: From baseline to approximately 24 months ]The time from date of first dose until the date of death due to any cause
- Disease control rate (DCR) [ Time Frame: From baseline to approximately 24 months ]The percentage of subjects who have a best response of confirmed CR or PR or who have stable disease for at least 5 weeks after start of treatment, based on BICR data
- Lowest concentration (Ctrough) of adavosertib [ Time Frame: Pre-dose (60 minutes prior to dosing) on Day 5 of Cycles 1 and 2 (each cycle is 21 days) ]Lowest plasma concentration of adavosertib before next dose
- Maximum concentration (Cmax) of adavosertib [ Time Frame: 2 hours post-dose on Day 5 of Cycles 1 and 2 (each cycle is 21 days) ]Maximum plasma concentration of adavosertib after oral dosing
- Number of subjects with adverse events (AE) and serious AEs [ Time Frame: From baseline to post-treatment follow-up (30 days after last dose) ]Assessment of AEs, vital signs, clinical laboratory values, electrocardiogram findings, and AEs leading to dose interruptions, dose reductions, and dose discontinuations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years to 130 Years (Adult, Older Adult)|
|Sexes Eligible for Study:||Female|
|Accepts Healthy Volunteers:||No|
- Subjects must be aged ≥ 18 years of age inclusive, at the time of signing the informed consent.
- Histologically confirmed recurrent or persistent USC. Subjects with carcinosarcomas are not eligible.
- Evidence of measurable disease as per RECIST v1.1.
- At least 1 prior platinum-based chemotherapy regimen for the management of USC. Prior receipt of immune checkpoint inhibitors, vascular endothelial growth factor (VEGF) inhibitors and human epidermal growth factor receptor 2 (HER2) targeted therapy is allowed. There is no restriction on the number of prior lines of systemic therapy.
- Eastern Cooperative Oncology Group performance (ECOG) status 0-1.
- Life expectancy ≥ 12 weeks.
- Subjects must have normal organ and marrow function at baseline, within 7 days prior to study drug administration.
- Consent to submit and provide a mandatory Formalin-fixed paraffin-embedded tumor sample for central testing.
- Female subjects who are not of childbearing potential and women of childbearing potential who agree to use adequate contraceptive measures.
- Any underlying medical condition and uncontrolled intercurrent illness that would impair the ability of the subject to receive study treatment, as judged by the investigator.
- With the exception of alopecia, any unresolved toxicities from prior therapy greater than Common Terminology Criteria for Adverse Events (CTCAE) Grade 1 at the time of starting study treatment.
- Unable to swallow oral medications.
- Spinal cord compression or metastases unless asymptomatic, stable, and not requiring steroids for at least 4 weeks prior to start of study intervention.
- Subjects with current signs or symptoms of bowel obstruction, including sub-occlusive disease, related to underlying disease.
Any of the following cardiac diseases currently or within the last 6 months:
- Unstable angina pectoris
- Acute myocardial infarction
- Congestive heart failure
- Conduction abnormality not controlled with pacemaker or medication
- Significant ventricular or supraventricular arrhythmias
- History of Torsades de pointes unless all risk factors that contributed to Torsades have been corrected.
- a) Resting corrected QTc interval using the Fridericia formula (QTcF) > 480 msec, or b) congenital long QT syndrome.
- Immunocompromised subjects.
- Subjects with known active hepatitis (ie, hepatitis B or C).
Prior treatment with any of the following:
- Cell cycle checkpoint inhibitor.
- Anticancer treatment drug ≤ 21 days (≤ 6 weeks for nitrosoureas or mitomycin C) or use of an investigational product within 5 half-lives prior to the first dose of adavosertib. For Programmed cell death-1 receptor (PD-1) /Programmed death-ligand 1 (PD-L1) inhibitors, a minimum of 28 days since last dose is required.
- Prescription or non-prescription drugs known as moderate to strong inhibitors / inducers of CYP3A4 within 2 weeks prior to the first dose of study treatment.
- Herbal medications 7 days prior to first dose of study treatment.
- Palliative radiotherapy with a limited field of radiation within 2 weeks or with wide field of radiation within 4 weeks prior to the first dose of study intervention.
- Major surgical procedures ≤ 28 days, or minor surgical procedures ≤ 7 days, prior to beginning study.
- Subjects with a known hypersensitivity or contraindication to adavosertib or any of the excipients of the product.
- Currently pregnant or breast-feeding.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04590248
|United States, California|
|Burbank, California, United States, 91505|
|Duarte, California, United States, 91010|
|La Jolla, California, United States, 92093|
|West Hollywood, California, United States, 90048|
|United States, Colorado|
|Aurora, Colorado, United States, 80045|
|United States, Iowa|
|Iowa City, Iowa, United States, 52242|
|United States, Louisiana|
|Covington, Louisiana, United States, 70433|
|United States, Massachusetts|
|Boston, Massachusetts, United States, 02215|
|United States, Minnesota|
|Rochester, Minnesota, United States, 55905|
|United States, New Jersey|
|New Brunswick, New Jersey, United States, 08903|
|United States, New York|
|Bronx, New York, United States, 10467|
|New York, New York, United States, 10065|
|United States, Washington|
|Spokane, Washington, United States, 99202|
|Vancouver, Washington, United States, 98684|
|Toronto, Canada, M5G 2M9|
|Dijon cedex, France, 21079|
|Marseille, France, 13273|
|Nice, France, 6189|
|Pierre Benite, France, 69495|
|Saint Herblain, France, 44805|
|Milan, Italy, 20141|
|Napoli, Italy, 80131|
|Roma, Italy, 00168|
|A Coruña, Spain, 15009|
|Barcelona, Spain, 08035|
|Barcelona, Spain, 08036|
|Pozuelo de Alarcón, Spain, 28223|
|Principal Investigator:||Joyce Liu, MD, MPH||Dana-Farber Cancer Institute|
|Other Study ID Numbers:||
|First Posted:||October 19, 2020 Key Record Dates|
|Last Update Posted:||February 23, 2023|
|Last Verified:||February 2023|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||Yes|
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Statistical Analysis Plan (SAP)
AstraZeneca will meet or exceed data availability as per the commitments made to the European Federation of Pharmaceutical Industries and Associations Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at:
When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at:
|Studies a U.S. FDA-regulated Drug Product:||Yes|
|Studies a U.S. FDA-regulated Device Product:||No|
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms, Cystic, Mucinous, and Serous
Molecular Mechanisms of Pharmacological Action